Reproductive outcomes in women with BRCA 1/2 germline mutations: A retrospective observational study and literature review

zu Verbundenen Objekten

Objective: To evaluate the reproductive outcomes of patients bearing BRCA-1 and BRCA-2 mutations. Methods: In this retrospective observational cohort study, we assessed data from BRCA-1 and BRCA-2 carriers, analyzing demographics, oncological history, and reproductive outcomes. Statistical analysis compared BRCA-1 and BRCA-2 carriers. A thorough review of the literature was carried out. Results: Fifty-eight patients were included. BRCA-1 and BRCA-2 mutations were equally distributed. Eighty-nine pregnancies occurred in our series, hesitated in 73 live births and 19 miscarriages. Mean age at first and last pregnancy was 27.8 ± 4.8 and 31.6 ± 4.8 years old. Thirty-nine patients have had at least one live birth (67.2%). Mean number of live births was 1.9 ± 0.6. Live birth rate (LBR) was 81.1% and miscarriage rate was 32.8%. Spontaneous fertility was unaltered, as evidenced by high LBR. Subgroup analysis revealed no significant differences between BRCA-1 and BRCA-2 carriers. Conclusions: Our results shows that spontaneous reproductive outcomes in BRCA-mutated patients are reassuring. Despite evidence indicating a decrease in ovarian reserve among BRCA patients, this factor seems to not impact spontaneous fertility negatively. Further research is needed, and individuals with BRCA mutations should consider early family planning and fertility preservation in case of partner absence.
Despite evidence indicating a decrease in ovarian reserve among BRCA patients, this factor seems to not impact their spontaneous fertility negatively.

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
Reproductive outcomes in women with BRCA 1/2 germline mutations: A retrospective observational study and literature review ; volume:19 ; number:1 ; year:2024 ; extent:11
Open medicine ; 19, Heft 1 (2024) (gesamt 11)

Urheber
Dellino, Miriam
D’Amato, Antonio
Battista, Gaia
Cormio, Gennaro
Vimercati, Antonella
Loizzi, Vera
Laganà, Antonio Simone
Damiani, Gianluca Raffaello
Favilli, Alessandro
Gerli, Sandro
La Forgia, Daniele
Daniele, Antonella
Agrifoglio, Vittorio
Cicinelli, Ettore
Vitagliano, Amerigo
Etrusco, Andrea

DOI
10.1515/med-2024-9999
URN
urn:nbn:de:101:1-2408241537059.492061568703
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:31 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Dellino, Miriam
  • D’Amato, Antonio
  • Battista, Gaia
  • Cormio, Gennaro
  • Vimercati, Antonella
  • Loizzi, Vera
  • Laganà, Antonio Simone
  • Damiani, Gianluca Raffaello
  • Favilli, Alessandro
  • Gerli, Sandro
  • La Forgia, Daniele
  • Daniele, Antonella
  • Agrifoglio, Vittorio
  • Cicinelli, Ettore
  • Vitagliano, Amerigo
  • Etrusco, Andrea

Ähnliche Objekte (12)

BRCA mutations: screening for germ-line founder mutations among early-onset Syrian breast cancer patients

BRCA mutations: screening for germ-line founder mutations among early-onset Syrian breast cancer patients

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers

BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies

BRCA germline mutation test for all woman with ovarian cancer?

BRCA germline mutation test for all woman with ovarian cancer?

Development and validation of ultrasound-based radiomics model to predict germline BRCA mutations in patients with breast cancer

Development and validation of ultrasound-based radiomics model to predict germline BRCA mutations in patients with breast cancer

Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study

Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study

Germline Mutations Predispose to Pediatric Medulloblastoma

Germline Mutations Predispose to Pediatric Medulloblastoma

Germline Mutations and Ancestry in Prostate Cancer

Germline Mutations and Ancestry in Prostate Cancer

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer

Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer

Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer

Providers’ perspectives on the reproductive decision-making of BRCA-positive women

Providers’ perspectives on the reproductive decision-making of BRCA-positive women

Verbundene Objekte